Company intelligence / Profile preview
GC Biopharma Corp
Yongin, Gyeonggi-do, South Koreagcbiopharma.us ↗
- Ownership
- Public · 006280
- Employees
- ~1766
- Development stage
- Phase 1
01
Overview
GC Biopharma has successfully developed and commercialized multiple products including vaccines (Hepatitis B, Epidemic Hemorrhagic Fever, Chicken pox), plasma derivatives, and treatments for rare diseases like Hunter syndrome
- Therapeutic areas
- GastroenterologyPulmonologyCardiovascularOncologyMetabolic DisordersRheumatologyImmunologyHematologyRare DiseasesNeurologyInfectious Diseases
- Modalities
- Plasma derivativesVaccinesRecombinant proteinsTherapeutic antibodiesCell therapy
- Industry
- Biotech
02
Drug pipeline
63 assets62 more assets in the full pipeline.
Request access →03
Partnerships
Chong Kun Dang PharmaceuticalDong-A ST Co.Kanaph Therapeutics
Beyond the preview
Go deeper on GC Biopharma Corp.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GC Biopharma Corp.